Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Gaboxetine** is an unapproved oral convenience kit marketed by Physician Therapeutics that co-packages fluoxetine hydrochloride capsules with GABAdone, a choline-containing medical-food formulation comprising amino acids and polyphenol ingredients for dietary management of sleep disorders, including sleep disorders associated with anxiety. Fluoxetine is a small-molecule selective serotonin reuptake inhibitor that inhibits the sodium-dependent serotonin transporter, increasing serotonergic signaling. The label presents fluoxetine indications including major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; however, the Gaboxetine product label states that FDA has not found the product safe and effective and that its labeling has not been FDA approved. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52057058-abdb-44ed-b60d-a718c97fbfda))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gaboxetine.